Medicinal Chemistry Journal of Medicinal Chemistry (ACS)
Indole CDK9 inhibitor W24 shrinks liver cancer xenografts
- Virtual screening plus structure-guided design yielded a new indole chemotype against CDK9, a thinly explored scaffold space for solid tumors.
- Lead W24 is a sub-nanomolar CDK9 inhibitor, with an encouraging first-pass kinase selectivity panel.
- In liver cancer cells it caused DNA damage and lowered the survival protein Mcl-1, driving cell death.
- It slowed HepG2 and Huh-7 xenograft growth at tolerated doses.
Sub-nanomolar potency on CDK9 means little until I see how it sits against CDK2, CDK7 and the other transcriptional CDKs, since the ATP pocket is so conserved. Mcl-1 loss is the expected on-target readout, but a short half-life protein drops with any transcription hit, so I'd want a rescue or a matched inactive analog. Next step: a clean off-target panel.
Paper: Journal of Medicinal Chemistry (ACS) ↗ Discovery and Optimization of Indole-Based CDK9 Inhibitors for Hepatocellular Carcinoma